메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Go, Seong Woo (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Kim, Boo Kyeong (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Lee, Sung Hak (Department of Pathology, The Catholic University of Korea College of Medicine) Kim, Tae-Jung (Department of Pathology, The Catholic University of Korea College of Medicine) Huh, Joo Yeon (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Lee, Jong Min (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Hah, Jick Hwan (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Kim, Dong Whi (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Cho, Min Jung (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Kim, Tae Wan (Department of Internal Medicine, The Catholic University of Korea College of Medicine) Kang, Ji Young (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
저널정보
대한결핵 및 호흡기학회 Tuberculosis and Respiratory Diseases 결핵 및 호흡기 질환 제75권 제6호
발행연도
2013.1
수록면
256 - 259 (4page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0